Serial pumping does not get the share price up.

First 12620 Last

Share
Profile

Follow
rvajna

8,805 Posts.

641

22/03/24

23:35

Post #: 73021909
Share

Originally posted by Taureanbull: ↑

Hawkbar, The company doesn’t need to arrive at its final destination for the share price to move. As I have pointed out several times, the company does want to move onto the NASDAQ. It does have major international investors watching the OASIS trial closely. The company has also employed a corporate strategist.. A lot of money has already been spent preparing for a NASDAQ listing. And we have several trial results for our platforms being released this year.

The stock market is very cable of relating a stock without seeing a big pharma deal. This company has made incredible progress in the last two years. At some stage this progress will be reflected in the share price, Whilst it may seem like it’s sat idle forever this does not predict forward shareprice movement. As with the big effort to push our clinical programs ahead, after we get the results released, the company will use these results as a catalyst to push our ahead our corporate strategy and the share price will respond accordingly.

There is a reason we are seeing this flurry of media activity. Did you also note in the last video of Leslie Chong, mentioned “ a recent presentation to US investors”. Whilst we haven’t seen a video, posted here and do not have any further information, it does hint that she is presenting to them. And it’s unlikely to be Mums and Dads . The US has a quite large and sophisticated BIOTECH focussed investment community. As opposed to Australia that has a very thin sprinkling of mums and dads.

It’s very much my experience that the SP,of a successful Biotexh will rerate rapidly when institutional investors come on board . This hasn’t happened to IMU as yet, in part because dour domestic fund managers don’t touch Biotexh. But US investors have a huge appetite for future disruptive technologies.

And that is exactly what IMU is about to unveil. The results of trials . That’s is why they dumped ALA , because our drugs are so good they don’t need ALA. All of this has been presented in the 4 videos and assorted other social media posts and announcements.

I personally got a lot from Dr Bradley Glovers presentation. And further as I shared with this board, I was lucky enough to have the opportunity to meet him and ask why he joined IMU. He reinforced his reasons again yesterday.

As he is a highly qualified expert on Celular Therapies , I’m very happy to take his word , that we have an amazing portfolio of assets here, And I’m happy to trust that major investors will see this opportunity resulting in a major relating of our share price.A Market Cap of just US$520M is clearly ridiculously low.

Expand

Serial pumping does not get the share price up.

IMU Price at posting: 10.5¢ Sentiment: Hold Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

ASX Market Open: Australian bourse to fall as subdued Wall Street awaits rate cut decision | September 18, 2024

HVN

Harvey Norman clocks subdued gains as Echo Law's junk warranty class action kicks off

CXU

Cauldron discovers shallow uranium up to 2km at WA's Yanrey

88E

HotCopper users smell capital raising as 88 Energy says "significant update" at Phoenix

PAR

FDA hands Paradigm Biopharma guidance to re-jig phase 3 osteo trial – or is it a delay?

There are more pages in this discussion • 2,977 more messages in this thread...

First 12620 Last

Add IMU (ASX) to my watchlist

(20min delay)
Last 4.9¢		Change 0.001(2.08%)		Mkt cap ! $360.7M

Open	High	Low	Value	Volume
4.9¢	5.0¢	4.8¢	$1.065M	21.79M

Buyers (Bids)

No.	Vol.	Price($)
31	3973914	4.8¢

Sellers (Offers)

Price($)	Vol.	No.
4.9¢	857055	21

View Market Depth

No.	Vol.	Price($)
30	3926576	0.048
33	2392456	0.047
37	3386214	0.046
40	8584594	0.045
8	3563272	0.044

Price($)	Vol.	No.
0.049	854486	20
0.050	1889899	16
0.051	775501	14
0.052	570056	10
0.053	2438131	12

Last trade - 11.22am 18/09/2024 (20 minute delay)

IMU (ASX) Chart

Serial pumping does not get the share price up.

ASX Market Open: Australian bourse to fall as subdued Wall Street awaits rate cut decision | September 18, 2024

Harvey Norman clocks subdued gains as Echo Law's junk warranty class action kicks off

Cauldron discovers shallow uranium up to 2km at WA's Yanrey

HotCopper users smell capital raising as 88 Energy says "significant update" at Phoenix

FDA hands Paradigm Biopharma guidance to re-jig phase 3 osteo trial – or is it a delay?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Serial pumping does not get the share price up.

Top Stories

ASX Market Open: Australian bourse to fall as subdued Wall Street awaits rate cut decision | September 18, 2024

Harvey Norman clocks subdued gains as Echo Law's junk warranty class action kicks off

Cauldron discovers shallow uranium up to 2km at WA's Yanrey

HotCopper users smell capital raising as 88 Energy says "significant update" at Phoenix

FDA hands Paradigm Biopharma guidance to re-jig phase 3 osteo trial – or is it a delay?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News